In this review:
LungART shows adjuvant radiotherapy should not be the standard of care in resected stage 3AN2 NSCLC
KRASG12C inhibition shows promise in heavily pretreated NSCLC
Front-line pembrolizumab doubles survival duration in PD-L1-positive NSCLC
Reduced risk of CNS recurrence with adjuvant osimertinib in EGFR-mutated NSCLC
CROWN supports lorlatinib for front-line treatment of ALK-positive NSCLC
No PFS advantage to consolidation immunotherapy in limited stage SCLC
CHRYSALIS examines amivantamab plus lazertinib for EGFR-mutated NSCLC
Combination osimertinib plus bevacizumab shows no PFS benefit in patients who progress on EGFR TKIs
Nivolumab boosts efficacy of bevacizumab and chemotherapy in NSCLC
Front-line cemiplimab confers survival and PFS advantages in PD-L1+ NSCLC
Please login below to download this issue (PDF)